Recruiting
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants - CN012-0012
Mis à jour:
17 février, 2026
|
ClinicalTrials.gov
Résumé imprimable
Détails de l’essai
-
Phase 1
Phase
-
Sexe(s)
-
18-65
Tranche d’âge
-
3
Site(s)
-
Recruiting
Options de traitement
Principaux critères d’éligibilité
Inclusion Criteria: - Participant must be healthy male and female (INOCBP) participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (VS), and clinical laboratory determinations. - Participant must be a normal/extensive, intermediate, poor, or ultrarapid CYP2D6 metabolizer. - Participant must have body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. Exclusion Criteria: - Participants must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population reference ranges. - Other protocol-defined Inclusion/Exclusion criteria apply.